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Abstract
Background: Tuberculosis (TB) is a major global health problem and drug resistance compromises the efforts to
control this disease. Pyrazinamide (PZA) is an important drug used in both first and second line treatment regimes.
However, its complete mechanism of action and resistance remains unclear.
Results: We genotyped and sequenced the complete genomes of 68 M. tuberculosis strains isolated from unrelated
TB patients in Peru. No clustering pattern of the strains was verified based on spoligotyping. We analyzed the
association between PZA resistance with non-synonymous mutations and specific genes.
We found mutations in pncA and novel genes significantly associated with PZA resistance in strains without pncA
mutations. These included genes related to transportation of metal ions, pH regulation and immune system
evasion.
Conclusions: These results suggest potential alternate mechanisms of PZA resistance that have not been found in
other populations, supporting that the antibacterial activity of PZA may hit multiple targets.
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Background
Tuberculosis (TB) caused by the Mycobacterium tubercu-
losis bacilli is one of the most important global infectious
diseases. Approximately one third of the global population
has latent TB infection, and 10% of infected people will
eventually develop active TB disease in their lifetime [1].
While other first line anti-TB drugs affect fast
growing metabolically active bacilli, pyrazinamide
(PZA) is particularly effective against non-replicating
persistent. M. tuberculosis. This unique feature
facilitates the shortening of the duration of TB
chemotherapy including PZA from 12 to 6 months
[2]. The mechanism of action and resistance to PZA
is not completely understood. PZA is a pro-drug
which enters into M. tuberculosis by passive diffusion
[3], and it is converted into its active form, pyrazinoic
acid (POA) by the action of pyrazinamidase (PZAse)
[4]. POA is released into extracellular space by an ef-
flux system, where it is protonated to HPOA provided
that the extracellular environment is acidic [3]. Exter-
nal HPOA diffuses back across the membrane of M.
tuberculosis through an electrical potential gradient,
releasing the proton in the cytosol. The combination
of POA accumulation of POA protonation of the
cytosol produces a lethal effect through the disruption
of membrane permeability and reduced membrane
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potential. This affects transport of nutrients [5], and
interference of trans-translation by binding to the
ribosomal protein RpsA [6] and competing with the
tmRNA [7].
It was clearly demonstrated that loss of PZAse activity
highly correlates with PZA resistance in M. tuberculosis
[4, 8–10]. PZAse malfunction is caused by mutations in
its coding gene (pncA) [11], as well as in its promoter re-
gion compromising the expression of the protein [12],
resulting in lack of conversion of PZA into POA [13].
Previous studies have demonstrated that POA efflux rate
varies amongst M. tuberculosis strains [14] and its quan-
titative variability is significantly associated with the level
of PZA resistance [15].
Although PZA resistance in M. tuberculosis is mostly
associated with mutations in pncA, other genes have re-
cently been found involved in the mechanism of action
of PZA [16], while there are potential other factors that
may alter the PZA susceptibility. These include factors
for ROS-induced mutagenesis, selective treatment pres-
sure or immune evasion genes [17].
In the present study, we sequenced and annotated the
complete genomes from 68 strains of M. tuberculosis
isolated from Peruvian TB patients, with known PZA
susceptibility. We analyzed the statistical association be-
tween PZA resistance with specific mutations and genes.
Particular attention was given to specific gene families
with potential biological relationship with the PZA
mechanism of action.
Methods
M. tuberculosis samples and PZA resistance
We selected well-characterized strains from our M. tuber-
culosis strains bank. A total of 68 M. tuberculosis clinical
isolates recovered from different unrelated patients from
Lima, Peru with active tuberculosis and with previous
PZA susceptibility results were selected for genome ana-
lysis and further studies. From these 68 strains, 26 strains
were PZA resistant and 42 strains were PZA susceptible
(Table 1). 29 strains had BACTEC 460 TB susceptibility
(21 resistant and 8 susceptible). Forty-six strains had
BACTEC 960-MGIT susceptibility (10 resistant and 36
susceptible). Five strains were resistant in BACTEC 960-
MGIT and in BACTEC 460 TB. Two strains were suscep-
tible in BACTEC 960-MGIT and in BACTEC 460 TB. No
one strain had a discrepant result between BACTEC 960-
MGIT and in BACTEC 460 TB.
Genotyping and phylogenetic analysis
Spoligotyping films were blindly interpreted by two differ-
ent readers. Reads were repeated when a discrepancy was
detected. To identify the relationship of strains, and to
verify that no bias due to the presence of particular gen-
omic variants is present, a phylogenetic analysis was
performed to identify clusters and orphan strains. The
lineage (clade and SIT code, (shared-type number corre-
sponding to a spoligotype)) of each strain was identified
by the classification of the 43-digits spoligotyping code de-
fined in the SITVIT database (Institut Pasteur of
Guadeloupe). To show the strain diversity, strains were
categorized in groups according to their clades and SIT
codes. A distance-tree of the spoligotypes was constructed
using the multi-state discrete-characters parsimony
method of the software Phylip v 3.695. The distribution of
spoligotypes, stratified by susceptible/resistance strains,
was analyzed in a histogram with standard errors.
Genome sequencing and data processing
Genomic DNA was extracted from M. tuberculosis strains
by the proteinase K digestion method as described previ-
ously [18]. DNA from samples were sequenced at the King
Abdullah University of Science and Technology (KAUST)
using Illumina HiSeq2000 paired end technology, yielding
an average of nineteen million 76 bp reads (IQR 9–23 mil-
lion) per genome. High quality sequencing reads (>Q30)
were assembled by reference (M. tuberculosis H37Rv ref-
erence genome: GenBank NC_000962), using NextGENe
(version 2.2.0, SoftGenetics), with default parameters.
Chimeric and low quality reads (less than Q30), were dis-
carded to reduce the likelihood of assembly errors and
thus the appearance of false SNPs. After paired end map-
ping, we obtained 362X fold coverage (IQR 177–463), and
97.7% of each genome was covered with at least 5X fold.
Regions of low sequencing coverage (2.3% of genome, less
than 5X fold) were ignored. Using the sequence align-
ments, SNPs and insertions and deletions were identified
using NextGENe (version 2.2.0, SoftGenetics). These vari-
ants were classified for their occurrence in coding or non-
coding regions, and whether mutations led to synonymous
or non-synonymous aminoacid changes. Only non-
synonymous SNPs and insertions/deletions in coding re-
gions were considered for the subsequent analysis.
Compilation of a special set of genes
It is currently accepted that POA is expelled outside
the mycobacteria by an efflux pump system, however
the identity of this pump is not yet known. We com-
piled a set of reported M. tuberculosis efflux pump
coding genes, and also a set of homologues to efflux
pumps reported in the literature for different organ-
isms, (identity ≥25% in blast).
M. tuberculosis PZAse is a metalloenzyme. Our pre-
vious studies suggest that PZAse may be activated by
a metallochaperone in vivo (to be published). We
compiled a set of metallochaperones and divalent ions
transporter proteins. Some of them have already been
described in other species, including yodA, zinT,
mntA, mntC, sitA, troA, psaA, btuF, feoB, SBP, mntH,
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Table 1 Strains analyzed in the study, experimental test for resistance and mutations in pyrazinamidase
Resistance profile Mutations in pncA/PZAse
Isolate BACTEC 460 TB BACTEC 960 TB-MGIT Res PZA Gene Protein Promoter
CSV4519 R – 1 – – –
CSV4644 R – 1 T152C H51R –
CSV5769 R R 1 C232A G78C –
CSV10399 R R 1 A280G F94 L –
CSV11678 R – 1 G185A P62L –
LE486 R – 1 T35G D12A –
LE492 – R 1 T35G D12A –
LN180 – R 1 A392C V131G –
LN2358 – R 1 A545C L182 W –
LN3756 R – 1 T403G T135P –
MDRDM260 – R 1 T403G T135P –
MDRDM627 – R 1 – – –
MDRDM1098 R R 1 C145T D49N –
MDRMA2491 R R 1 T35C D12G –
ME1473 R – 1 A100C Y34D –
TBDM425 R – 1 C145T D49N –
TBV5000 R – 1 – – –
TBV5362 R – 1 – – –
TBV5365 R – 1 – – –
SLM036 R R 1 A190C Y64D –
SLM040 R – 1 T170C H57R –
SLM056 R – 1 – – –
SLM060 R – 1 – – T-11C
SLM063 R – 1 A416G V139A –
SLM088 R – 1 – – –
SLM100 R – 1 – – T-11C
CSV383 S – 0 A40C C14G
CSV3611 S – 0 – –
CSV9577 S – 0 – –
LE13 – S 0 T478C T160A
LE63 – S 0 – –
LE76 – S 0 – –
LE79 – S 0 – –
LE103 S S 0 – –
LE371 – S 0 – –
LE410 – S 0 – –
LN55 – S 0 A40C C14G
LN317 – S 0 – –
LN763 – S 0 – –
LN2978 – S 0 – –
LN3584 – S 0 – –
LN3588 – S 0 – –
Sheen et al. BMC Genomics  (2017) 18:769 Page 3 of 11
nhlF and corA [19]. Homologues of metallochaperones
in M. tuberculosis included Rv2059 and Rv0106. As
metal ion transporters we included the metallopro-
teins: Rv2060, Rv0106, nicT, nurA, furB, SBP, mntH,
and the cation transporter ATPase family: CtpI, CtpE,
CtpC, CtpG and CtpV.
Special attention was given to genes that have been
previously proposed as associated to the mechanism
of action of PZA: FAS-1 (Rv2524c), rpsA (Rv1630),
gpsL (Rv2783c), mmpL4 (Rv0450c), panD (Rv3601c),
hadC (Rv0637), pstC2 (Rv0929), Acyl-CoA synthetase
(Rv1683) and the hypothetical proteins Rv2731 and
Rv3169 [5, 7].
Data analysis
Association analyses were performed both at a SNP level
and gene level independently.
SNP level analysis
For each specific non-synonymous mutation, we com-
pared the proportion of resistant and susceptible strains
harboring a particular mutation. For the resistant strains,
we found the number of strains with the specific mutation
(a) and without the mutation (b). For the susceptible
strains we found the number of strains with the specific
mutation (c) and without the mutation (d).
Three analyses were performed: (1) a proportion test for
a binomial distribution, to compare the frequencies of a
particular mutation among the resistant and susceptible
strains (proportions a/(a + b) and c/(c + d) respectively); (2)
an estimation of the Odds Ratio (ad)/(bc) in order to iden-
tify the increased risk of PZA resistance associated to the
presence of a particular mutation and; (3) calculation of the
Youden Index (sensitivity + specificity −1) [a/(a + c) + d/
(b + d) – 1], which determines the overall capacity of the
mutation to correctly classify PZA resistance.
Table 1 Strains analyzed in the study, experimental test for resistance and mutations in pyrazinamidase (Continued)
Resistance profile Mutations in pncA/PZAse
Isolate BACTEC 460 TB BACTEC 960 TB-MGIT Res PZA Gene Protein Promoter
LN3589 – S 0 – –
LN3668 – S 0 – –
LN3672 – S 0 – –
LN3695 – S 0 – –
LN1100 – S 0 – –
LN1856 S S 0 T143G K48 T
LN2900 – S 0 – –
MDRDM827 – S 0 – –
MDRMA203 – S 0 – –
MDRMA701 – S 0 – –
MDRMA863 – S 0 – –
MDRMA1565 – S 0 – –
MDRMA2019 – S 0 – –
MDRMA2082 – S 0 – –
MDRMA2260 – S 0 – –
MDRMA2441 – S 0 – –
TBDM1506 – S 0 – –
TBDM2189 – S 0 – –
TBDM2444 – S 0 – –
TBDM2487 – S 0 – –
TBDM2489 – S 0 – –
TBDM2699 – S 0 – –
TBDM2717 – S 0 – –
TBV4766 S – 0 – –
TBV4768 S – 0 – –
TBV4952 S – 0 – –
We are only showing the non-synonymous mutations in the gene pncA and its promoter, and the corresponding amino acid change in the
protein pyrazinamidase
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Gene level analysis
For each annotated gene, we estimated the association
between the presence of at least one mutation in a
particular gene and PZA resistance. For each gene we
calculated the following parameters. For the resistant
strains: The number of strains with at least one non-
synonymous mutation in this gene (a), and the num-
ber of strains with no mutation in this gene (b). Simi-
larly, for the susceptible strains: The number of
strains with at least one non-synonymous mutation in
this gene (c), and the number of strains with no mu-
tation in this gene (d). We calculated these parame-
ters for every annotated gene of the M. tuberculosis
genome. Similarly as above, three analyses were per-
formed: (1) a proportion test for a binomial distribu-
tion, to compare the frequencies of a particular gene
with at least one mutation among the resistant and
susceptible strains; (2) estimation of the Odds Ratio
in order to identify the increased risk of PZA resist-
ance associated to the presence of at least one muta-
tion in a particular gene; and (3) calculation of the
Youden Index, which determines the overall capacity
of any mutation in a particular gene to correctly clas-
sify PZA resistance. All the statistics were performed
with a 5% significance level.
Results
Phylogenetic analysis
The phylogenetic analysis confirmed that the isolated
strains are not related and do not cluster by PZA sus-
ceptibility (Fig. 1). In addition, the distribution of the
clades and SIT stratified by PZA resistance, confirmed
that PZA resistance is not exclusive and do not cluster
into any specific clade (Additional file 1: Table S1 and
Fig. 2 respectively). This suggests that potential bias due
to the presence of particular genomic variants or trans-
mission of particular clones, in the resistant strains is
not likely happening in the selected sample.
Identification of specific mutations in pncA/PZAse
Seventeen non-synonymous mutations in pncA were
found only in resistant strains: D12A, T135P and D49N in
two strains and D12G, Y34D, H51R, H57R, P62L, Y64D,
G78C, F94 L, V131G, V139A and L182 W in only one
strain. Only the mutations D12A, T135P and D49N were
significantly associated with PZA-resistance (P = 0.034).
Three non-synonymous mutations were found only in
PZA-susceptible strains: mutation C14G in two strains
and mutations K48 T and T160A in only one strain. No
non-synonymous mutation in pncA appeared in both re-
sistant and susceptible strains. Only one mutation in pncA
Fig. 1 Distances-based tree based on spoligotyping profile of the strains
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promoter (T-11C) was found in two PZA-resistant strains
(SLM60 and SLM100) without compromise of the coding
region but was associated to a compromise in PZAse ex-
pression [12].
We identified seven PZA-resistant strains with no mu-
tations in the pncA gene neither in its promoter
(CSV4519, MDRDM627, TBV5000, TBV5362, TBV5365,
SLM056 and SLM088). Five of them (colored in green in
Table 2) also with no mutations in the specific set of
genes selected. Detailed results are shown in Table 2.
Association of mutations with PZA-resistance
In the 68 genomes we found 53,515 DNA mutations in
2763 genes (20,763 synonymous and 32,752 non-
synonymous mutations). When considering only non-
synonymous mutations, there were 4118 different mutations
in 2242 genes. From these, 152 mutations were noninforma-
tive as they were present in all the strains analyzed.
From the 4118 non-synonymous mutations, 715 (com-
prised in 582 genes) appeared only in resistant strains.
The non-synonymous mutations that appeared in two or
more resistant strains (202 in total, comprised in 187
genes) resulted significantly associated with PZA resist-
ance (P < 0.05).
Those 202 mutations have the following frequency: 1
mutation (S1298 N in the protein PPE34) appeared in 4
strains; 8 mutations appeared in 3 strains and 193 muta-
tions appeared in 2 strains. The complete results of the
association analysis between resistance and mutations
expressed in odds ratios are shown in Additional file 2:
Table S2.
Association of genes with PZA resistance
The analysis by genes showed that pncA was the gene with
the highest association with PZA-resistance (P < 0.0001,
proportion test, OR = 17.94). Mutations only present in
resistant strains but not in susceptible strains were found
in 214 genes. Five of these mutated genes (rpsA, nrdR,
FadD22, Rv1556 and Rv3242c) appeared in 3 strains and
63 in 2 strains. These genes were significantly associated
with PZA resistance. The complete results of the associ-
ation analysis between resistance and genes expressed in
odds ratios are shown in Additional file 3: Table S3.
Additionally, intersecting the two-association analysis
described above, we found 110 genes significantly associ-
ated with PZA resistance at gene-level, that also har-
bored mutations significantly associated with PZA
resistance at mutation-level. The association analysis at
mutation level was reproduced for this set, excluding the
strains harboring mutations strongly related with PZA
resistance (mostly mutations in pncA, colored in orange,
in Table 2), calculating new association P-values. In
order to understand the biological relevance, these genes
were manually annotated to identify or predict their bio-
logical function (Additional file 4: Table S4). After ex-
cluding genes linked to resistance to other drugs and
pncA, we found a set of genes associated with PZA re-
sistance. Two of them (rpsA and gpsL) were recently re-
ported [7]. Most of them remain incompletely studied
and represent potential candidate genes to account for
alternate mechanisms of PZA resistance. This group of
genes was further analyzed. By manual annotation, cellu-
lar location and biological function were determined.
Fig. 2 Histogram with standard errors of the strains in the study, according their SIT code. In black (PZA resistant strains), in white (PZA susceptible strains)
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These genes coded for soluble and trans membrane pro-
teins, including functions of pH regulation, metallocha-
perones, and immune system evasion (Additional file 4:
Table S4). The genes that remained significantly associ-
ated with PZA resistance during the re-analysis after ex-
cluding the strains with critical mutations in pncA, were
Rv2505c, Rv2777c, Rv0735, Rv0787A, Rv0994, Rv1327c,
Rv1742, Rv2317, Rv2557, Rv2857c, Rv3362c, Rv3393,
Rv3410c, Rv3767c, Rv2646, Rv0668, and Rv0667.
Analysis of mutations in the special set of genes
For each of the mutations identified as significantly asso-
ciated with PZA resistance in genes of the special set of
interest, we verified if the strains harboring them also
showed mutations in pncA (colored in orange, Table 2).
Mutations found only in resistant strains, even they were
not statistically associated, were identified (Table 2).
Metallochaperones and metal ion transporters
Two non-synonymous mutations significantly associated
with PZA resistance (P = 0.034) were found in the pro-
tein CtpI in four resistant strains only (mutation A1469P
was found in strains MDRDM1098 and TBDM425, and
mutation N355 K was found in strains MDRDM260 and
LN3576) (Table 2). Nevertheless, these strains also
showed known pncA mutations that impairs the PZAse
activity [8] (strains MDRDM1098 and TBDM425 have
the mutation D49N, and strains MDRDM260 and
LN3576 have the mutation T135P in the PZAse).
The potential chaperon phoY1 showed the mutation
5YS statistically associated with PZA resistance, however
this mutation was found in strains (MDRDM260 and
LE3756), which have the mutation T135P in pncA. Re-
markably, the CtpE chaperone showed the mutation
A653E that occurs only in the PZA-resistant strain
SLM063 that harbors the pncA mutation V139A. Muta-
tion V139A has not been studied before, and its effect
on the PZAse activity is still unknown (Table 2).
Efflux pumps
Four non-synonymous mutations significantly associated
with PZA-resistance were found only in PZA-resistant
strains. Three of them were found in the genes
MmpL10, MmpL3, and Rv0194 (A302T, in strains
TBDM425 and MDRDM1098) (Table 2). However, these
strains showed pncA mutations (T135P and D49N) asso-
ciated with reduced PZAse activity [8].
The fourth mutation (the non-sense mutation W797*,
in strains SLM063 and LN180) was found in the gene
Rv0987. These strains showed the pncA mutations
V139A and V131G, respectively, for which their effect
on the PZAse activity is unknown.
Other reported proteins associated to PZA-resistance (RpsA,
PstC2, Fas, PanD)
Mutations in rpsA were only found in resistant strains
that harbored critical pncA mutations (D49N, T135P,
and H51R), which are known to cause PZA resistance.
Mutations in pstC2 were only found in a resistant
strain (P = 0.100) that harbored the pncA mutation
H57R associated with PZAse malfunction (Table 2).
Non-synonymous mutations were found in the fas
gene in resistant strains without pncA mutations. How-
ever, no significant association with PZA resistance was
found, probably due to the reduced sample size. We did
not find any non-synonymous mutation in panD, in any
of the strains analyzed in this study.
Discussion
In this study we analyzed 68 M. tuberculosis complete
genomes isolated from TB patients in Peru, and identi-
fied a set of novel mutations and genes significantly as-
sociated with PZA resistance in M. tuberculosis.
Although some of these mutations are found only in
PZA-resistant strains, some of these strains also har-
bored pncA critical mutations, confounding the contri-
bution to PZA resistance. To evaluate the effect of this
potential confounder, we conducted an analysis by in-
cluding and excluding these strains.
It is known that a mutation in pncA does not necessar-
ily cause a PZAse critical failure and PZA resistance.
Previous studies have shown mutations that partially re-
duced PZAse activity resulting in a minor level of PZA
resistance [8]. Therefore, some mutations in other genes,
harbored in strains with pncA mutations, may eventually
explain some level of PZA resistance in combination
with reduction of PZAse activity.
We found pncA mutations V139A, L182 W and
V131G, which have been previously reported in PZA-
resistant strains, although no studies about their effect
on PZAse activity are available yet. This leaves some
PZA-resistant strains whose resistance eventually could
not be explained by known genes and mechanisms.
Interestingly, this study found that several genes asso-
ciated with PZA-resistance are also associated with re-
sistance to other drugs including rifampin (rpoB),
ethambutol (embB) and isoniazid (katG). This observa-
tion is likely explained by the high correlation between
PZA resistance and multidrug resistance. In Peru, PZA
is administered in both first and second line drugs treat-
ment schemes, DOTS and DOTS Plus.
It is important to highlight that five PZA resistant
strains analyzed (MDRDM627, TBV5000, TBV5362,
TBV5365, and SLM056; Table 2) do not have mutations
in pncA neither in the reported genes included in the
special set of genes. After the P-value recalculation,
we found 2 genes statistically associated with PZA
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resistance in two of these strains: Rv2646 an integrase-
like enzyme, and the RNA polymerase component rpoC
for TBV5000 and TBV5365. It is likely that rpoC associ-
ation could be simply a confounding due to association
between MDR and PZA-resistance.
Notably, two strains showed no mutations in pncA but
in the genes of the special set. These genes are fadD35,
Rv2777c, sigL, Rv0787A, moeA1, glgE, Rv1742, uspB,
Rv2557, Rv2857c, Rv3362c, iunH, guaB3 and Rv3767c,
and were present in the strains LN180 and SLM063
which share the same spoligotype.
The annotation of this group of genes, reveals different
functions. Rv3659c is a putative membrane protein
within a conserved ATP-binding transporter region that
belongs to a Type IV pili – like operon and is homolo-
gous to VirB11 a gram negative protein from the type IV
secretion system essential for pathogenicity [20]. Silen-
cing Rv3659c increases macrophage apoptosis, while
Rv3659c activation reduces macrophage apoptosis due
to secretion of Rv3654c and Rv3655c, both required for
suppression of macrophage apoptosis inactivation [20].
Nevertheless, as yet there is no experimental evidence
that Rv3659c transports Rv3654c or Rv3655c. Rv3236c is
an integral membrane protein that functions as a K+/H
transporter that reduces phagosome ROS production by
releasing K+ to the phagosomal space [21]. It has been
proposed that K+ accumulation may be regulating
NOX2 activity from phagocytes [21] based on similar
events on neutrophils [22].
Rv2777c is a putative metal dependent hydrolase, re-
lated to bacilli persistence in macrophage and is up reg-
ulated during exposure to drugs that are active against
non-replicating persistence such as capreomycin and
PA-824 [23] and also in MDR strains [24]. Further ex-
perimental studies would be required in order to explore
the association of these genes with PZA resistance.
The identification of genes related to the regulation of
pH suggests an alternate mechanism of PZA resistance.
An acidic extracellular environment within granulomata
and macrophages in the latent state is necessary for PZA
to be effective. Protons carried by the protonated pyrazi-
noic acid are likely to produce intracellular acidification
that may be important in the mechanism of action of
PZA, in particular favoring the interaction between POA
and RpsA (Zimic, personal communication). Therefore,
factors associated to stabilize intracellular pH are likely
associated to PZA resistance.
Metal ions are necessary for PZAse activity and have a
direct effect in the PZA antibiotic mechanism [5, 25, 26]. It
has been speculated that the metalloenzyme PZAse of M.
tuberculosis coordinates divalent metal ions with the par-
ticipation of a metallochaperone [26]. We found genes as-
sociated to PZA resistance that are related with metal
transporting and appeared mutated only in PZA-resistant
strains. These proteins are members of Cation Transporter
ATPase family. This family is specialized in ion transport
(Mg+2, Zn+2, Co+2 and Ni+2) across membrane using ATP
hydrolysis energy [26]. In particular, CtpI (P < 0.05) and
CtpE (P < 0.10) (mutations in these genes appeared only in
resistant strains) are involved in the cellular homeostasis of
metal cations. Further studies would be required in order
to explore its association with PZA resistance.
We identified mutations associated to PZA-resistance in
four genes related to efflux pumps. These genes have been
reported as ABC-transporters or mmpL proteins and
drug-efflux pumps in M. tuberculosis. It is important to
highlight that Rv0194 showed a mutation (A968V) and
Rv3239c showed a mutation (P548S), in a PZA-resistant
strain with no mutation in pncA. Overexpression of
Rv0194 conferred multidrug resistance in M. smegmatis
by increasing drug extrusion or lipid transport across the
membrane [27]. It is important to further investigate if
pyrazinoic acid (POA), could be a substrate of the Rv0194
ABC transporter. Notably, the mutation A77S in the MgtE
efflux pump is only present in one resistant strain that
harbors the pncA mutation F94 L, which reduces the
PZAse activity partially [8]. Therefore, it is possible that
the mutation A77S in MgtE may partially contribute with
the resistance observed in this strain.
Shi et al. [7] discovered several proteins that bind to
POA, including RpsA, Rv2783c a bifunctional protein (poly-
ribonucleotide nucleotidyltransferase and ppGpp synthe-
tase) involved in mRNA degradation, Rv2731 a conserved
alanine and arginine rich domain protein, and Rv3169 a
hypothetical protein. Feuerriegel [28] sequenced the pncA
and RpsA genes of M. canettii, and found the mutations
T5A, T210A, P9P and E457E in RpsA, which were sug-
gested to be associated with PZA resistance [8]. It has been
found that that the mutation (L122E) in RpsA is not associ-
ated with PZA resistance [29]. Our data found mutations in
rpsA, however they were found in strains with pncA muta-
tions that cause PZAse malfunction.
A recent study analyzing strains isolated from TB pa-
tients in China, found that mutations in panD are closely
associated with PZA resistance [30]. This study showed
that of 5 PZA-resistant isogenic mutants without pncA or
rpsA mutations, all had panD mutations (A128S, V138A,
H21R, I49V, and E130G). Our data, did not show muta-
tions in panD.
A deep knowledge of the mutations associated with
PZA resistance would contribute with PZA-resistance
genome-sequencing testing efforts. A panel of SNPs
could be established by considering geographic specifi-
city, as it could be a differential lineage-related propen-
sity for mutations at certain sites, or lineage-related
propensity to allow compensation for otherwise lethal
mutations. As an increasing number of strains are tested,
more mutations in genes will be discovered. Although
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we cannot expect to have detected all of them in this
small sample size, these results are evidence of the
power of linking genomics with strong metadata, par-
ticularly phenotypic drug susceptibility. With the in-
creasing speed and the reducing cost of bacterial
genome sequencing, this could be an alternative to de-
termine drug susceptibility using molecular tests.
A better knowledge of the genetic basis of PZA resistance
will help clinicians to plan and deliver a more effective clin-
ical management to TB cases, reducing the likelihood of
drug resistance appearance. It also will aid the efforts for
the development of new generation molecular-based point-
of-care diagnostic assays with better sensitivity, specificity,
and cost-effectiveness.
Conclusions
In conclusion, this study identified new mutations and
genes from M. tuberculosis statistically significant associ-
ated with PZA resistance and potentially linked biologic-
ally. Our evidence confirms that the patterns of
mutations (SNPs and genes) associated with PZA resist-
ance found in Peru do not match with those recently
found in Asia, suggesting that the evolution of the
mechanisms of PZA resistance may have evolved differ-
ent in these two populations. The new mutations and
genes found in this study, represent a source of potential
alternate mechanisms of PZA resistance that need to be
further studied and could significantly improve the sen-
sitivity of molecular tests of PZA resistance.
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